Kwanan nan, wani majiyyaci da ke fama da cutar kansar pancreas wanda ya kasa samun magani da yawa a baya ya sami raguwar ciwon daji bayan ya sami maganin ƙwayoyin CAR-T na KD-496, tare da tabbatar da cewa an sami sassauci bayan kwana 180 bayan an yi masa magani.
A halin yanzu, har yanzu akwai gwaje-gwaje da yawa na asibiti na sabbin fasahohin yaƙi da cutar kansa a China waɗanda ke neman marasa lafiya. Tuntuɓi kan sabbin magunguna da fasahohi, zaku iya tuntuɓar Sashen Ƙasa da Ƙasa na Asibitin Oncology na Yankin Kudu na Beijing.
Lambar Waya: 4008803716
Shaidar WeChat: 17801183037
Imel:myimmnet@163.com
An gano cewa majinyaciyar, mace mai shekaru 73, ta kamu da ciwon kai a watan Yulin 2021, tare da toshewar bututun bile. An yi mata tiyatar cire ciki, inda aka sami wani babban nauyi mai girman kusan cm 3 a lokacin aikin cire ciki na pancreas. Binciken cututtuka ya tabbatar da cewa akwai adenocarcinoma mai bambancin matsakaici. Bayan tiyata, an yi mata allurar paclitaxel (nab-paclitaxel) tare da maganin S-1, sai kuma M108 + nab-paclitaxel + gemcitabine da LM108 tare da toripalimab. Tana da tarihin schizophrenia da ciwon suga, dukkansu an kula da su sosai da magunguna.
A watan Fabrairun 2025, majiyyaciyar ta sami allurar ƙwayoyin KD-496 CAR-T. A gwajin farko na ciwon daji makonni huɗu bayan haka, duk da tsufanta da kuma nauyin ciwon daji mai yawa (lalacewar da aka yi niyya ta 58 mm), ciwon da aka yi niyya ya ragu da kashi 34.5% daga asali. A rana ta 60, ciwon da aka yi niyya ya ƙara raguwa da kashi 37.9%, kuma a rana ta 90 da 180, ciwon ya ci gaba da raguwa da kashi 44.8%, yana ci gaba da samun wani ɓangare na amsawar (PR) ba tare da wata guba mai tsanani ga hanji ko jijiyoyi ba.
An yi wa wata majiyyaciya 'yar shekara 70 tiyata a watan Fabrairun 2023, inda bayan tiyatar ta nuna wani ciwon ulcerative adenocarcinoma mai matsakaicin bambanci zuwa mara kyau wanda ya riga ya zama ƙwayoyin lymph, peritoneum, da huhu duka, tare da ascites da pleural effusion (cutar da ta ci gaba, wadda ta fi yaduwa). Makonni takwas bayan tiyata, ta sami maganin SOX chemotherapy (oxaliplatin + S-1), amma yanayinta ya ci gaba. Gwaje-gwajen da aka yi mata na PX (paclitaxel) + PD-1 (immunotherapy) na tsawon zagaye huɗu, sai kuma capecitabine + nivolumab, shi ma ya kasa dakatar da ci gabanta. A ƙarshe, an ba nivolumab + fruquintinib (maganin hana angiogenesis), amma da ƙarancin inganci.
A rana ta 28 ta maganin CAR-T, ciwon ya ragu da kashi 47.3% idan aka kwatanta da wanda aka yi kafin a fara magani, inda ya sami cikakken martani (PR). A rana ta 60, ciwon ya ci gaba da raguwa da kashi 41.9%, yana ci gaba da tabbatar da PR, wanda ke nuna ci gaba da kuma ingantaccen magani.
Wata majiyyaciya 'yar shekara 55 da ke fama da cutar kansar ciki ta yi tiyatar laparoscopic radical gastrectomy a watan Nuwamba na 2023, inda bayan tiyatar ta nuna cewa ba ta da bambanci sosai tsakanin adenocarcinoma da cutar sankarar signet-ring cell carcinoma (mai matuƙar illa). Ta gwada hanyoyin chemotherapy da yawa + immunotherapy, ciki har da oxaliplatin + capecitabine + sintilimab, oxaliplatin + leucovorin + sintilimab, nab-paclitaxel + sintilimab + fruquintinib, da kuma irinotecan monotherapy. Duk da haka, a watan Fabrairu na 2025, yanayinta ya ci gaba da sauri, wanda ya sa magungunan gargajiya ba su da tasiri.
Daga nan ta sami maganin ƙwayoyin CAR-T, kuma a rana ta 28, ciwon ya ragu da kashi 31.8% idan aka kwatanta da wanda aka yi kafin a yi masa magani, inda aka samu wani ɓangare na martanin cutar (PR), kuma an samu nasarar shawo kan cututtuka.
A halin yanzu, har yanzu akwai gwaje-gwaje da yawa na asibiti na sabbin fasahohin yaƙi da cutar kansa a China waɗanda ke neman marasa lafiya. Tuntuɓi kan sabbin magunguna da fasahohi, zaku iya tuntuɓar Sashen Ƙasa da Ƙasa na Asibitin Oncology na Yankin Kudu na Beijing.
Lambar Waya: 4008803716
Shaidar WeChat: 17801183037
Imel:myimmnet@163.com
Lokacin Saƙo: Yuli-31-2025